GeoVax Labs, Inc. has begun engaging with global health and preparedness organizations to explore potential future procurement of its GEO-MVA vaccine candidate for mpox and smallpox preparedness programs. The company has initiated discussions and is soliciting interest from international organizations that influence or directly procure mpox/smallpox vaccines, which play key roles in recommending or directly procuring vaccines for national preparedness stockpiles and international outbreak response programs.
This outreach reflects growing global recognition of the need to diversify supply of Modified Vaccinia Ankara vaccines used for protection against mpox and smallpox. Currently, global supply of MVA vaccines is concentrated in a single commercial manufacturer. Global preparedness programs for smallpox and mpox vaccines represent a potential multi-billion-dollar procurement market supported by national stockpiles, military preparedness programs, and international health organizations. Governments have invested billions of dollars in medical countermeasure stockpiles over the past two decades, and demand for MVA-based vaccines is expected to further expand as mpox continues to emerge as a recurring global health threat.
GeoVax believes that initiating engagement with procurement and preparedness organizations represents an important transition from development toward commercialization planning, reflecting growing confidence in the GEO-MVA program and the potential for the vaccine to contribute to global preparedness stockpiles following successful completion of the planned Phase 3 study, scheduled to initiate in the second half of 2026. The company's GEO-MVA program has progressed through an extensive regulatory dialogue with the European Medicines Agency, culminating in scientific advice in support of an expedited development pathway based on a single immunobridging trial to the licensed MVA vaccine.
David Dodd, Chairman and Chief Executive Officer of GeoVax, stated that the EMA carefully evaluated the scientific evidence over an extended period before confirming an expedited pathway. He believes their guidance validates both the scientific foundation of GEO-MVA and the growing recognition that expanding the global MVA vaccine supply is an important public health priority. Dodd noted that the company has been encouraged by the positive response received from global health organizations and preparedness agencies as these discussions were initiated, viewing this engagement as an endorsement of the progress made and the potential of GEO-MVA to help address the current worldwide need for expanded MVA vaccine supply.
The discussions initiated by GeoVax occur amid growing policy dialogue regarding the strategic importance of expanding global MVA vaccine manufacturing capacity. GeoVax believes GEO-MVA has the potential to become a strategically important medical countermeasure supporting both global public health preparedness and national biodefense initiatives. Recent mpox outbreaks have reinforced the understanding that mpox is not a single episodic event, but rather an evolving infectious disease threat with potential for continued geographic expansion and recurrence. As a result, governments and international health organizations are increasingly emphasizing the need for manufacturing diversification and supply redundancy for vaccines used in outbreak response and biodefense preparedness.
In the United States, policymakers and defense stakeholders have increasingly recognized that no domestic manufacturing capability currently exists for MVA vaccines, a gap with implications for both civilian preparedness and military readiness. Dodd emphasized that establishing additional MVA manufacturing capability is increasingly viewed as an important component of global preparedness, with growing interest from public health organizations, governments, and defense stakeholders who recognize the strategic importance of supply diversification. For more information about the company, visit https://www.geovax.com.
